Lexaria Bioscience Corp.
LEXX
$0.62
$0.000.36%
NASDAQ
| 11/30/2025 | 08/31/2025 | 05/31/2025 | 02/28/2025 | 11/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 174.00K | 174.00K | 174.00K | 183.90K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 174.00K | 174.00K | 174.00K | 183.90K |
| Cost of Revenue | -- | 0.00 | -- | -- | 2.70K |
| Gross Profit | -- | 174.00K | 174.00K | 174.00K | 181.20K |
| SG&A Expenses | 902.30K | 766.70K | 1.21M | 1.24M | 918.70K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.57M | 2.65M | 3.92M | 2.93M | 2.87M |
| Operating Income | -1.57M | -2.47M | -3.75M | -2.75M | -2.69M |
| Income Before Tax | -1.60M | -2.70M | -3.79M | -2.72M | -2.71M |
| Income Tax Expenses | 1.80K | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.60M | -2.70M | -3.79M | -2.72M | -2.71M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 2.50K | 1.40K | 1.50K | 3.80K | 2.90K |
| Net Income | -1.60M | -2.70M | -3.79M | -2.71M | -2.70M |
| EBIT | -1.57M | -2.47M | -3.75M | -2.75M | -2.69M |
| EBITDA | -1.56M | -2.45M | -3.72M | -2.75M | -2.66M |
| EPS Basic | -0.07 | -0.14 | -0.21 | -0.15 | -0.16 |
| Normalized Basic EPS | -0.05 | -0.08 | -0.13 | -0.10 | -0.10 |
| EPS Diluted | -0.07 | -0.14 | -0.21 | -0.15 | -0.16 |
| Normalized Diluted EPS | -0.05 | -0.08 | -0.13 | -0.10 | -0.10 |
| Average Basic Shares Outstanding | 21.38M | 19.58M | 18.30M | 17.51M | 16.67M |
| Average Diluted Shares Outstanding | 21.38M | 19.58M | 18.30M | 17.51M | 16.67M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |